DUBLIN – Inhaled drug delivery specialist Vectura Group plc could be adding at least $89.7 million to its coffers after a U.S. jury found that its partner, Glaxosmithkline plc, infringed a Vectura patent in three of its Ellipta-branded products for respiratory disease.